Apollo Takes Minority Stake in Bayer Contraceptives Unit for 3 Billion Euros

The private equity firm acquires the position in Bayer's long-acting reversible contraceptives business to supply equity capital without touching the parent company's broader debt load.

Bayer has agreed to sell a minority stake in its long-acting reversible contraceptives division to funds managed by Apollo for 3 billion euros. The transaction supplies fresh equity directly into the unit rather than the parent balance sheet. It arrives as Bayer continues to manage legacy litigation exposure and existing debt maturities.

Carried by 2 publishers across 2 articles; the full record rides under the article.

Truth Foundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.